Study of VX-985 in Subjects With Chronic Hepatitis C

Chronic Hepatitis C Clinical Trial

Official title:

A Phase 1b, Randomized, Double-Blind, Placebo-Controlled, Multiple-Dose Study of VX-985 in Subjects With Genotype 1 Chronic Hepatitis C

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01144936
• Other study ID #: VX09-985-101
• Status: Completed
• Phase: Phase 1
• First received: June 14, 2010
• Last updated: March 8, 2011
• Start date: June 2010
• Est. completion date: October 2010

Study information

• Verified date: March 2011
• Source: Vertex Pharmaceuticals Incorporated
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Food and Drug Administration
• Study type: Interventional

Clinical Trial Summary

The purpose of this study it to evaluate the safety and tolerability of VX-985 in HCV subjects. This study will also evaluate the antiviral activity and pharmacokinetic profile of VX-985.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 21
• Est. completion date: October 2010
• Est. primary completion date: October 2010
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years to 64 Years

Eligibility

Inclusion Criteria:

• Subjects who are male or females of non-childbearing potential aged 18 to 64 years(inclusive) with a body mass index (BMI) between 18 and 32 (kg/m2)

• Certain subjects must agree to use acceptable contraceptive methods as specified in protocol

• Subjects who are treatment naïve and are infected with genotype 1 chronic hepatitis C

• Subjects must be in good health and have normal laboratory values as judged by investigator

• Subjects must not have clinically significant abnormal results for physical examination

Exclusion Criteria:

• Subjects must not have received approved or experimental HCV therapy

• Subjects must not have evidence of hepatic decompensation: history of ascites, hepatic encephalopathy, or bleeding esophageal varices

• Subjects must not have any known history of other cause of significant liver disease including hepatitis B, drug or alcohol-related cirrhosis, etc

• Subjects must not be diagnosed with or have suspected hepatocellular carcinoma

• Subjects must not have histologic evidence of hepatic cirrhosis on any liver biopsy or test capable of detecting cirrhosis within the past 2 years

• Subjects with a known history or other evidence of severe retinopathy or clinically significant ophthalmological disorder

• Subjects must not have a history of any illness that might confound the results of the study or pose an additional risk in administering study drug(s) to the subject e.g. history of cardiovascular or central nervous system disease, ongoing psychiatric disorder, poorly controlled diabetes, etc

• Subject must not have taken any of the prohibited medications within the specified time before study start or take certain medications (including herbal supplements) during the study

• Subjects must not have a history of drug or alcohol abuse or addiction within 6 months before the start of dosing, or test positive for alcohol or drugs of abuse

• Subjects must not have donated or had a significant loss of blood within 56 days of the start of dosing, or donated more than 1 unit of plasma within 7 days before the start of dosing

• Subjects must not consume excessive amounts of caffeine

• Subjects must not have participated in a clinical study involving administration of either an investigational or a marketed drug within 2 months

• Subjects who are female and have a positive pregnancy test and/or who are considered to be of childbearing potential or are nursing.

• Subjects that have a female partner who is pregnant, nursing, or planning to become pregnant during the study or shortly after the study

Study Design

Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment

Related Conditions & MeSH terms

• Chronic Hepatitis C
• Hepatitis
• Hepatitis A
• Hepatitis C
• Hepatitis C, Chronic
• Hepatitis, Chronic

Intervention

Drug:
• VX-985 or matching placebo
low dose
• VX-985 or matching placebo
high dose
• VX-985 or matching placebo
dose TBD

Locations

Country	Name	City	State
United States	Maryland	Baltimore	Maryland
United States	Kansas	Overland Park	Kansas
United States	Washington	Tacoma	Washington

Sponsors (1)

Lead Sponsor	Collaborator
Vertex Pharmaceuticals Incorporated

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Safety and tolerability (vital signs, 12-lead electrocardiograms, physical examinations, laboratory assessments, and adverse events)		10-13 days	Yes
Secondary	Plasma pharmacokinetic parameters of VX-985		10-13 days	No
Secondary	HCV RNA levels		5-7 months	No